Donepezil Effect on Visual Attention and Training

NCT ID: NCT01738295

Last Updated: 2017-06-05

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-01-31
• Study Completion Date: 2015-08-31

Brief Summary

The present proposal investigates the role of the cholinergic system (the neurotransmitter acetylcholine) in improving vision and visual attention. Vision results from a complex processing of particular stimuli of the visual field. Attention enhances and prolongs the neural representations of visual input in the visual cortex. It has recently been shown that attention in the visual cortex depends on cholinergic mechanisms. The action of acetylcholine in the visual cortex consists in enhancement of the responsiveness to thalamocortical inputs, depression of local neuronal connections or extrastriate feedback projections and induction of gamma synchronisation. The investigators hypothesize that these effects are associated with long-term changes in functional connectivity in the visual cortex, visual attention and visual learning (improvement of the visual capacities).

In the present proposal, the investigators will test whether the administration of donepezil (Aricept, 5mg), a drug that increases the level of acetylcholine in the brain, will enhances the perceptual-cognitive abilities of young adult subjects. Perceptual-cognitive performance will be assessed in a multiple object tracking (MOT) task in a 3D automatic virtual environment. MOT is a task where observers are asked to maintain attentional focus on a limited number of preselected subgroup of elements in a dynamic scene. Multifocal attentional mechanisms are necessary to process the information. The task will be tested five time at one week interval to test whether donepezil and training improved the task performance of the subject, i.e. lead to perceptual learning. This study could help establish an intervention procedure to improve visual performance of subjects that need it.

Detailed Description

Stages of a given perceptual-cognitive task (from Faubert and Sidebottom, Journal of Clinical Sport Psychology, 2012, 6, 85-102):

1. a predetermined number of spheres (typically eight) are presented in a 3D dimensional virtual volumetric cube space. The spheres are typically all identical.

2. a subset of spheres (typically four) is indexed via highlighting for a brief period of 1 s.

3. the spheres return to their original color and start moving within the restricted 3D virtual space. During this movement, the spheres can collide and consequently suddenly change direction, and they can cross over others, thus occluding their view.

4. the spheres stop moving after a predetermined time, and the observer has to identify the spheres that were initially indexed with halos. The subject is then given feedback on the response by having the spheres identified by revealing the appropriate indexed stimuli.

The main task starts at a given speed, and if all four spheres are not correctly identified, the next trial will be slower. If the four spheres are correctly identified, then the next trial will be faster. Trials are repeated like this following a staircase procedure, and ultimately, a speed threshold is established.

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: DOUBLE

Study Groups

Donepezil

Donepezil administration. In this group Donepezil (Aricept pill, 5 mg) will be orally administrated 3h before each experiment (1 week intervals)

Group Type: ACTIVE_COMPARATOR

Donepezil administration

Intervention Type: DRUG

Lactose pill

Placebo administration. In this group, placebo (lactose pill) will be orally administrated 3h before each experiments (1 week intervals)

Group Type: PLACEBO_COMPARATOR

Placebo administration

Intervention Type: DRUG

Interventions

Donepezil administration

Intervention Type: DRUG

Placebo administration

Intervention Type: DRUG

Other Intervention Names

Aricept, Pfizer; Lactose pill

Eligibility Criteria

Inclusion Criteria

• good general health
• 17 < body mass index < 25
• visual acuity 6/6
• visual stereoscopy > 50
• standard visual field

Exclusion Criteria

• pregnancy or breast feeding
• use of any drug or St John's wort
• smoking
• asthma
• pulmonary obstruction
• cardiovascular impairment
• attention troubles
• ocular diseases
• epilepsy
• lactose intolerance
• absorption of grapefruit juice

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 35 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Université de Montréal

OTHER

Sponsor Role: lead

Responsible Party

Elvire Vaucher

Associate professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Elvire Vaucher, PhD

Role: STUDY_DIRECTOR

Université de Montréal

Jocelyn Faubert, PhD

Role: STUDY_DIRECTOR

Université de Montréal

Isabelle Legault, PhD

Role: PRINCIPAL_INVESTIGATOR

Université de Montréal

Mira Chamoun, MSc

Role: PRINCIPAL_INVESTIGATOR

Université de Montréal

Locations

School of optometry / Université de Montréal

Montreal, Quebec, Canada

Countries

Canada

Other Identifiers

12-084-CERES

Identifier Type: -

Identifier Source: org_study_id